IP Library Patent Application 14711359
Patent Application
App. No. 14/711,359

AQUEOUS BUFFER-FREE BIVALIRUDIN COMPOSITIONS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
14/711,359
Abstract

The present invention is directed to aqueous bivalirudin compositions and methods of administration of such compositions. The aqueous bivalirudin compositions of the present invention have a pH of about 3 to about 5 and are substantially free of buffer. Further compositions of the present invention include bivalirudin compositions comprising at least one stabilizer having a pH of about 3 to about 5. Additional compositions of the present invention include bivalirudin compositions comprising at least one stabilizer substantially free of buffer. Compositions of the present invention also include bivalirudin compositions substantially free of buffer. The invention is also directed to methods of treatment comprising administering a bivalirudin composition of the present invention. The invention is further directed to the use of the bivalirudin compositions of the present invention as an anticoagulant in a patient in need thereof.

Claims (32)

1 .- 24 . (canceled)

25 . An aqueous bivalirudin composition comprising:

a) bivalirudin or salts thereof and

b) at least one or more stabilizers,

wherein the composition is substantially free of buffer.

26 . (canceled)

27 . The composition of claim 25 wherein the stabilizer is a nonelectrolyte selected from the group consisting of monosaccharides, disaccharides, sugar alcohols, and mixtures thereof, or an electrolyte selected from the group consisting of uniunivalent electrolytes, diunivalent electrolytes, unidivalent electrolytes, and ditrivalent electrolytes, and mixtures thereof.

28 . (canceled)

29 . The composition of claim 27 wherein the stabilizer is sodium chloride and is present in an amount from about 8 mg/mL to about 14 mg/mL.

30 .- 32 . (canceled)

33 . The composition of claim 29 wherein sodium chloride is present in an amount from of about 9 mg/mL or about 13 mg/mL.

34 . (canceled)

35 . The composition of claim 25 wherein the pH is about 3 to about 5.

36 . The composition of claim 35 wherein the pH is about 3.9 to about 4.4.

37 . The composition of claim 35 wherein the pH is about 4.25.

38 .- 40 . (canceled)

41 . The composition of claim 25 wherein no more than about 5% of bivalirudin is degraded upon storage at a temperature of about 2° C. to about 8° C. over 12 months.

42 . An aqueous bivalirudin composition comprising bivalirudin or salts thereof, wherein the composition is substantially free of buffer and has a pH of about 3 to about 5.

43 . The composition of claim 42 wherein the pH is about 3.9 to about 4.4

44 . The composition of claim 42 wherein the pH is about 4.25.

45 . The composition of claim 42 further comprising at least one or more of a stabilizer.

46 . The composition of claim 45 wherein the stabilizer is sodium chloride.

47 . The composition of claim 46 comprising 6 mg/mL to 14 mg/mL of sodium chloride.

48 . The composition of claim 47 wherein sodium chloride is present in an amount from about 8 mg/mL to about 10 mg/mL.

49 . The composition of claim 47 wherein sodium chloride is present in an amount from about 12 mg/mL to about 14 mg/mL.

50 . The composition of claim 47 wherein sodium chloride is present in an amount from of about 9 mg/mL or about 13 mg/mL.

51 . (canceled)

52 . The composition of claim 42 further comprising a stabilizer in an amount such that the osmolality of the composition is about 200 to about 1000 mOsm/kg.

53 . (canceled)

54 . The composition of claim 42 wherein the composition has a shelf-life of at least about 12 months.

55 . The composition of claim 42 wherein no more than about 5% of bivalirudin is degraded after storage at 2° C.-8° C. for about 12 months.

56 - 127 . (canceled)

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Apr 1, 2025
From: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
To: EAGLE PHARMACEUTICALS, INC.
Reel/Frame 070703/0524 →
SECURITY INTEREST Recorded Jan 26, 2017
From: EAGLE PHARMACEUTICALS, INC.
To: JPMORGAN CHASE BANK, N.A., AS ADMINISTRATIVE AGENT
Reel/Frame 041095/0554 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 15, 2015
From: CHEN, FENG-JING; KRILL, STEVEN L.
To: EAGLE PHARMACEUTICALS, INC.
Reel/Frame 036569/0069 →